Pharmaceuticals Global On demand · 24-48h

Global Menadiol Diacetate Tablets Market Strategic Research Report

Global Menadiol Diacetate Tablets Market Strategic Research …
$3,500 USD
Market Research Reports
Strategic Research Report
Global Menadiol Diacetate Tablets Market
$19.672025
3.8%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: 15% Sulfacetamide Sodium Eye Drops, 10% Sulfacetamide Sodium Eye Drops

By Application: Hospital, Clinic, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Jiangsu Jibei Pharmaceutical Co., Ltd., Beijing Yanjing Pharmaceutical Co., Ltd., Ruiyang Pharmaceutical Co., Ltd., Henan Runhong Pharmaceutical Co., Ltd., Harbin Pharmaceutical Group Pharmaceutical Factory, Sichuan Sichuan University West China Pharmaceutical Co., Ltd., China Resources Double Crane Pharmaceutical Co., Ltd., Zhejiang Ruixin Pharmaceutical Co., Ltd., China Resources Zizhu Pharmaceutical Co., Ltd., Xi'an Lijun Pharmaceutical Co., Ltd., Tianfang Pharmaceutical Co., Ltd., Diao Group Chengdu Pharmaceutical Co., Ltd., Wuxi Jiyu Shanhe Pharmaceutical Co., Ltd., Hubei Ouli Pharmaceutical Co., Ltd., Southwest Pharmaceutical Co., Ltd.

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 106 pages
Market size 2025
$19.67
Million USD
Forecast CAGR
3.8%
2025-2032
Forecast 2032
$25.5
Projected
リージョン
5
Asia Pacific · Latin America · MEA · Europe · North America

概観

Scope of the Report

The global Menadiol Diacetate Tablets market size is predicted to grow from US$ 19.67 million in 2025 to US$ 25.39 million in 2032; it is expected to grow at a CAGR of 3.8% from 2026 to 2032.

Menadiol diacetate tablets are a vitamin K drug that is mainly used to prevent and treat bleeding tendency or hypoprothrombinemia caused by vitamin K deficiency. It helps restore normal blood coagulation function by promoting the liver to synthesize coagulation factors II, VII, IX and X. This drug is often used in neonatal bleeding, vitamin K deficiency caused by long-term use of antibiotics, and reversal of certain anticoagulant treatments.

Global key Menadiol Diacetate Tablets players cover Jiangsu Jibei Pharmaceutical Co., Ltd., Beijing Yanjing Pharmaceutical Co., Ltd., Ruiyang Pharmaceutical Co., Ltd., Henan Runhong Pharmaceutical Co., Ltd., Harbin Pharmaceutical Group Pharmaceutical Factory, etc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Menadiol Diacetate Tablets market?

What factors are driving Menadiol Diacetate Tablets market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Menadiol Diacetate Tablets market opportunities vary by end market size?

How does Menadiol Diacetate Tablets break out by Type, by Application?

This report presents a comprehensive overview of the global Menadiol Diacetate Tablets market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

Segment by Application

  • Hospital
  • Clinic
  • Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Menadiol Diacetate Tablets market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Hospital, Clinic, Other evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Menadiol Diacetate Tablets Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 3.8%
Regional growth momentum
Market share by segment
Key metrics
Base value
$19.67
2025
Forecast
$25.5
2032
CAGR
3.8%
2025–2032
リージョン
5
global
Key companies
Jiangsu Jibei Pharmaceutical Co., Ltd.Beijing Yanjing Pharmaceutical Co., Ltd.Ruiyang Pharmaceutical Co., Ltd.Henan Runhong Pharmaceutical Co., Ltd.Harbin Pharmaceutical Group Pharmaceutical FactorySichuan Sichuan University West China Pharmaceutical Co., Ltd.China Resources Double Crane Pharmaceutical Co., Ltd.Zhejiang Ruixin Pharmaceutical Co., Ltd.
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
15% Sulfacetamide Sodium Eye Drops10% Sulfacetamide Sodium Eye Drops
By Application
HospitalClinicOther

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 15% Sulfacetamide Sodium Eye Drops
  • 3.1.3 10% Sulfacetamide Sodium Eye Drops
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Hospital
  • 4.1.3 Clinic
  • 4.1.4 Other
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Jiangsu Jibei Pharmaceutical Co., Ltd.
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Beijing Yanjing Pharmaceutical Co., Ltd.
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Ruiyang Pharmaceutical Co., Ltd.
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Henan Runhong Pharmaceutical Co., Ltd.
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Harbin Pharmaceutical Group Pharmaceutical Factory
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Sichuan Sichuan University West China Pharmaceutical Co., Ltd.
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 China Resources Double Crane Pharmaceutical Co., Ltd.
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Zhejiang Ruixin Pharmaceutical Co., Ltd.
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 China Resources Zizhu Pharmaceutical Co., Ltd.
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Xi'an Lijun Pharmaceutical Co., Ltd.
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Tianfang Pharmaceutical Co., Ltd.
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Diao Group Chengdu Pharmaceutical Co., Ltd.
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Wuxi Jiyu Shanhe Pharmaceutical Co., Ltd.
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Hubei Ouli Pharmaceutical Co., Ltd.
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Southwest Pharmaceutical Co., Ltd.
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Menadiol Diacetate Tablets market?
The global Menadiol Diacetate Tablets market is estimated at US$ 19.67 million in 2025 (base year) and is projected to reach US$ 25.39 million by 2032.
How fast is the Menadiol Diacetate Tablets market expected to grow?
The market is expected to grow at a CAGR of 3.8% from 2026 to 2032, expanding from US$ 19.67 million in 2025 to US$ 25.39 million in 2032, roughly 1.3 times its base-year value.
What does the Menadiol Diacetate Tablets market cover?
Menadiol diacetate tablets are a vitamin K drug that is mainly used to prevent and treat bleeding tendency or hypoprothrombinemia caused by vitamin K deficiency. It helps restore normal blood coagulation function by promoting the liver to synthesize coagulation factors II, VII, IX and X. This drug is often used in neonatal bleeding, vitamin K deficiency caused by long-term use of antibiotics, and reversal of certain anticoagulant treatments.
How is the Menadiol Diacetate Tablets market segmented by type?
By type, the market is segmented into 15% Sulfacetamide Sodium Eye Drops and 10% Sulfacetamide Sodium Eye Drops.
What are the key applications of Menadiol Diacetate Tablets?
Key applications covered include Hospital, Clinic and Other.
Which companies are profiled in the Menadiol Diacetate Tablets market report?
Key players profiled include Jiangsu Jibei Pharmaceutical Co., Beijing Yanjing Pharmaceutical Co., Ruiyang Pharmaceutical Co., Henan Runhong Pharmaceutical Co., Harbin Pharmaceutical Group Pharmaceutical Factory, Sichuan Sichuan University West China Pharmaceutical Co., China Resources Double Crane Pharmaceutical Co. and Zhejiang Ruixin Pharmaceutical Co., among 15 companies covered in total.
What geographies does the Menadiol Diacetate Tablets market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Menadiol Diacetate Tablets?
What factors are driving Menadiol Diacetate Tablets market growth, globally and by region?
Who should buy the Menadiol Diacetate Tablets market report?
The report is intended for manufacturers and solution providers, distributors and end users in Hospital, Clinic and Other, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Menadiol Diacetate Tablets market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from $3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.